Claims
- 1. A method for treating a patient with leukemia comprising administering to a patient that has been previously treated with a Brc-Abl tyrosine kinase inhibitor a therapeutically effective amount of a compound having the formula I:
- 2. A method for treating a patient with leukemia comprising administering to a patient that has been previously treated with imatinib mesylate (STI-571) and has become resistant to the imatinib mesylate (STI-571) treatment, a therapeutically effective amount of a compound having the formula I:
- 3. The method according to claim 1, wherein R is H.
- 4. The method according to claim 1, wherein B is cytosine.
- 5. The method according to claim 1, wherein R is H and B is cytosine.
- 6. The method according to claim 1, wherein said compound of formula I is at least 95% free of the (+) form.
- 7. The method according to claim 1, wherein said compound of formula I is at least 97% free of the (+) form.
- 8. The method according to claim 1, wherein said compound of formula I is at least 99% free of the (+) form.
- 9. The method according to claim 1, wherein said compound of formula I is substantially in the form of the (−) enantiomer.
- 10. The method according to claim 1, wherein said compound of formula I is β-L Oddc.
- 11. The method of claim 1, wherein the leukemia is a chronic myelogenous leukemia.
- 12. The method of claim 1, wherein the leukemia is an acute myelogenous leukemia.
- 13. The method of claim 1, wherein the leukemia is a chronic myelogenous leukemia in blastic phase.
- 14. The method according to claim 2, wherein R is H.
- 15. The method according to claim 2, wherein B is cytosine.
- 16. The method according to claim 2, wherein R is H and B is cytosine.
- 17. The method according to claim 2, wherein said compound of formula I is at least 95% free of the (+) form.
- 18. The method according to claim 2, wherein said compound of formula I is at least 97% free of the (+) form.
- 19. The method according to claim 2, wherein said compound of formula I is at least 99% free of the (+) form.
- 20. The method according to claim 2, wherein said compound of formula I is substantially in the form of the (−) enantiomer.
- 21. The method according to claim 2, wherein said compound of formula I is β-L Oddc.
- 22. The method of claim 2, wherein the leukemia is a chronic myelogenous leukemia.
- 23. The method of claim 2, wherein the leukemia is an acute myelogenous leukemia.
- 24. The method of claim 2, wherein the leukemia is a chronic myelogenous leukemia in blastic phase.
- 25. A method for treating leukemia in a patient comprising administering to a patient that has been previously treated with a Brc-Abl tyrosine kinase inhibitor a therapeutically effective amount of at least one compound of general formula I
- 26. The method according to claim 25, wherein the leukemia is chronic myelogenous leukemia and acute myelogenous leukemia.
- 27. The method according to claim 25, wherein the leukemia is acute myelogenous leukemia.
- 28. The method according to claim 25, wherein the leukemia is chronic myelogenous leukemia in blastic phase.
- 29. The method according to claim 25, wherein the compound of formula I and the further therapeutic agent are administered sequentially.
- 30. The method according to claim 25, wherein the compound of formula I and the therapeutic agent are administered simultaneously.
- 31. The method according to claim 2, wherein the compound of formula (I) is administered to the patient that has been previously treated with imatinib mesylate (STI-571) and has become resistant to the imatinib mesylate (STI-571) treatment at a dose of 8 mg/m2 over 30 minutes intravenous infusion per day for 5 days.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/330,891 filed Nov. 2, 2001 which is hereby incorporated in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60330891 |
Nov 2001 |
US |